Brief: CSL To Invest $1.5 Bln In U.S. To Manufacture Plasma-Derived Therapies
18/11/2025 14:48
Nov 18 (Reuters) - CSL Ltd CSL.AX: TO INVEST APPROXIMATELY $1.5B IN U.S. TO MANUFACTURE PLASMA-DERIVED THERAPIES Further company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX